Joseph L. Kim

6.2k total citations · 4 hit papers
21 papers, 3.9k citations indexed

About

Joseph L. Kim is a scholar working on Molecular Biology, Oncology and Hepatology. According to data from OpenAlex, Joseph L. Kim has authored 21 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Oncology and 5 papers in Hepatology. Recurrent topics in Joseph L. Kim's work include Melanoma and MAPK Pathways (4 papers), Protein Kinase Regulation and GTPase Signaling (4 papers) and Hepatitis C virus research (4 papers). Joseph L. Kim is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Protein Kinase Regulation and GTPase Signaling (4 papers) and Hepatitis C virus research (4 papers). Joseph L. Kim collaborates with scholars based in United States, China and South Korea. Joseph L. Kim's co-authors include S.K. Burley, Dimitar B. Nikolov, Christoph Lengauer, Nicolas Stransky, Stefanie S. Schalm, Ethan Cerami, Chao Lin, Kurt Morgenstern, Kathy Hsiao and Mark A. Murcko and has published in prestigious journals such as Nature, Cell and Nature Communications.

In The Last Decade

Joseph L. Kim

21 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Co-crystal structure of TBP recognizing the minor groove of a TATA element

1993 901 citations Joseph L. Kim, Dimitar B. Nikolov et al. Nature profile →
X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex

1995 698 citations Joseph L. Kim, Kathy Hsiao et al. Cell profile →
The landscape of kinase fusions in cancer

2014 657 citations Nicolas Stransky, Ethan Cerami et al. Nature Communications profile →
Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding

1998 518 citations Joseph L. Kim, Kurt Morgenstern et al. Structure profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph L. Kim United States	14	2.9k	697	416	319	317	21	3.9k
Priscilla L. Yang United States	26	2.3k 0.8×	789 1.1×	385 0.9×	241 0.8×	191 0.6×	48	4.6k
Louie Naumovski United States	36	2.6k 0.9×	1.2k 1.8×	176 0.4×	343 1.1×	451 1.4×	99	3.9k
Steven B. Kanner United States	37	2.2k 0.8×	668 1.0×	287 0.7×	148 0.5×	367 1.2×	87	4.7k
Jürgen Mestan Switzerland	31	2.3k 0.8×	1.1k 1.6×	79 0.2×	314 1.0×	285 0.9×	56	5.1k
Christine Lukacs United States	21	3.9k 1.3×	2.5k 3.6×	131 0.3×	257 0.8×	637 2.0×	35	5.3k
Donna S. Shewach United States	38	2.8k 1.0×	1.8k 2.5×	145 0.3×	843 2.6×	690 2.2×	98	5.0k
William T. Windsor United States	23	1.5k 0.5×	876 1.3×	158 0.4×	212 0.7×	97 0.3×	42	2.5k
Brian D. Marsden United Kingdom	30	2.7k 0.9×	642 0.9×	58 0.1×	275 0.9×	136 0.4×	65	3.9k
Alex Kentsis United States	37	3.4k 1.2×	799 1.1×	64 0.2×	217 0.7×	397 1.3×	103	4.6k
Steven Rosenberg United States	27	1.8k 0.6×	636 0.9×	177 0.4×	175 0.5×	1.9k 5.8×	49	4.1k

Countries citing papers authored by Joseph L. Kim

Since Specialization

Citations

This map shows the geographic impact of Joseph L. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph L. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph L. Kim more than expected).

Fields of papers citing papers by Joseph L. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph L. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph L. Kim. The network helps show where Joseph L. Kim may publish in the future.

Co-authorship network of co-authors of Joseph L. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph L. Kim. A scholar is included among the top collaborators of Joseph L. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph L. Kim. Joseph L. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hatlen, Megan, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.. (2019). Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. Cancer Discovery. 9(12). 1686–1695. 90 indexed citations

Gardino, Alexandra K., Erica N Evans, Joseph L. Kim, et al.. (2018). Targeting kinases with precision. Molecular & Cellular Oncology. 5(3). e1435183–e1435183. 12 indexed citations

Rahal, Rami, Erica N Evans, Wei Hu, et al.. (2016). Abstract 2641: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors. Cancer Research. 76(14_Supplement). 2641–2641. 10 indexed citations

Liu, Longbin, Matthew R. Lee, Joseph L. Kim, et al.. (2016). Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling. Bioorganic & Medicinal Chemistry. 24(10). 2215–2234. 13 indexed citations

Hagel, Margit, Chandra Miduturu, Michael P. Sheets, et al.. (2015). First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discovery. 5(4). 424–437. 247 indexed citations

Stransky, Nicolas, Ethan Cerami, Stefanie S. Schalm, et al.. (2015). Abstract 954: The landscape of kinase fusions in cancer. Cancer Research. 75(15_Supplement). 954–954. 1 indexed citations

Evans, Erica N, Brian L. Hodous, Alexandra K. Gardino, et al.. (2015). Abstract 791: BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants. Cancer Research. 75(15_Supplement). 791–791. 18 indexed citations

Stransky, Nicolas, Ethan Cerami, Stefanie S. Schalm, Joseph L. Kim, & Christoph Lengauer. (2014). The landscape of kinase fusions in cancer. Nature Communications. 5(1). 4846–4846. 657 indexed citations breakdown →

Liu, Liqin, Gordon Moody, Jeanne Pistillo, et al.. (2011). Abstract 1975: Discovery of a potent and selective Jak2 inhibitor that suppresses GM-CSF-induced STAT5 phosphorylation and Erythropoietin-induced reticulocytosis in vivo. Cancer Research. 71(8_Supplement). 1975–1975. 1 indexed citations

10.

Carnahan, Josette, Pedro J. Beltran, Carol Babij, et al.. (2010). Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth. Molecular Cancer Therapeutics. 9(8). 2399–2410. 58 indexed citations

11.

Carnahan, Josette, Pedro J. Beltran, Carol Babij, et al.. (2010). Abstract 21: Selective and potent inhibitors of the mutant B-Raf pathway paradoxically stimulate the MAPK pathway in wild-type B-Raf cells. Cancer Research. 70(8_Supplement). 21–21. 2 indexed citations

12.

Smith, Adrian L., Nick A. Paras, Qi Huang, et al.. (2009). Selective Inhibitors of the Mutant B-Raf Pathway: Discovery of a Potent and Orally Bioavailable Aminoisoquinoline. Journal of Medicinal Chemistry. 52(20). 6189–6192. 90 indexed citations

13.

Perni, Robert B., Lawrence F. Courtney, David D. Deininger, et al.. (2003). Inhibitors of hepatitis C virus NS3·4A protease 1. Non-Charged tetrapeptide variants. Bioorganic & Medicinal Chemistry Letters. 13(22). 4059–4063. 25 indexed citations

14.

Lin, Chao & Joseph L. Kim. (1999). Structure-Based Mutagenesis Study of Hepatitis C Virus NS3 Helicase. Journal of Virology. 73(10). 8798–8807. 81 indexed citations

15.

Zhu, Xiaotian, Joseph L. Kim, John Newcomb, et al.. (1999). Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure. 7(6). 651–661. 205 indexed citations

16.

Kwong, Ann D., et al.. (1998). Hepatitis C virus NS3/4A protease. Antiviral Research. 40(1-2). 1–18. 102 indexed citations

17.

Kim, Joseph L., et al.. (1998). Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure. 6(1). 89–100. 518 indexed citations breakdown →

18.

Kim, Joseph L., et al.. (1995). X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell. 82(3). 507–522. 698 indexed citations breakdown →

19.

Kim, Joseph L. & S.K. Burley. (1994). 1.9 Å resolution refined structure of TBP recognizing the minor groove of TATAAAAG. Nature Structural & Molecular Biology. 1(9). 638–653. 184 indexed citations

20.

Kim, Joseph L., Dimitar B. Nikolov, & S.K. Burley. (1993). Co-crystal structure of TBP recognizing the minor groove of a TATA element. Nature. 365(6446). 520–527. 901 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact